The patient-to-patient variability is a significant reason that previous p53-based therapies have failed in the clinic, as most tumors are p53 deficient but not all cancer cells in a tumor may be p53-depleted, while others may have mutated p53 that overrides wild type p5337. This evidence concerns the gene TP53 and cancer.